The HOPE randomized trial shows that CT‑perfusion–selected patients treated with intravenous alteplase at 4.5–24 hours (no planned thrombectomy) had higher 90‑day functional independence (40.3% vs 26.3%), with increased symptomatic intracranial hemorrhage but no higher mortality.